Antidepressants Explained: How SSRIs, SNRIs, and Other Classes Work – and What to Expect When You Start One

Antidepressants are prescribed to approximately 13% of Americans over the age of 12 – making them one of the most commonly used medication classes in the country. They’re also among the most misunderstood. Myths about antidepressants causing personality changes, creating permanent dependency, or being reserved for severe cases keep many people who would benefit from them from ever starting. Meanwhile, unrealistic expectations about how quickly they work and what they actually do lead others to stop them prematurely.

This article covers how the major classes of antidepressants work, what’s actually known about their mechanisms, what to expect during the first weeks, the real side effect picture, and how prescribing decisions are made.

A Note on What Antidepressants Treat

Despite the name, antidepressants are used for far more than depression. They’re FDA-approved and evidence-supported for:

• Major depressive disorder (MDD)
• Generalized anxiety disorder (GAD)
• Panic disorder
• Social anxiety disorder
• Obsessive-compulsive disorder (OCD)
• Post-traumatic stress disorder (PTSD)
• Premenstrual dysphoric disorder (PMDD)
• Bulimia nervosa
• Chronic pain conditions (neuropathic pain, fibromyalgia)
• Migraine prevention
• Menopausal hot flashes
• Bedwetting in children (certain tricyclics)

This breadth reflects that the neurotransmitter systems these medications target – primarily serotonin and norepinephrine – are involved in mood regulation, pain processing, anxiety, and several other functions simultaneously.

The Major Classes

SSRIs (Selective Serotonin Reuptake Inhibitors)

SSRIs are the most prescribed antidepressants – first-line treatment for depression, anxiety disorders, PTSD, OCD, and PMDD.

Common SSRIs:

• Fluoxetine (Prozac) – longest half-life (4-6 days), easiest to taper
• Sertraline (Zoloft) – most prescribed antidepressant in the US
• Escitalopram (Lexapro) – slightly more selective, often well-tolerated
• Citalopram (Celexa) – similar to escitalopram; higher doses have QT prolongation risk
• Paroxetine (Paxil) – shorter half-life, more discontinuation symptoms; has anticholinergic effects
• Fluvoxamine (Luvox) – used primarily for OCD

Mechanism: SSRIs block the serotonin transporter (SERT), preventing reuptake of serotonin from the synaptic cleft back into the presynaptic neuron. This increases serotonin availability in the synapse.

The paradox of the 2-6 week delay: SSRIs raise synaptic serotonin within hours of the first dose. Yet antidepressant effects take 2-6 weeks to develop. This delay – which would make no sense if simply “low serotonin” caused depression – suggests the therapeutic effect requires downstream adaptations: receptor density changes, neuroplasticity (including hippocampal neurogenesis), and altered gene expression triggered by sustained serotonin signaling. The mechanism of antidepressant action is genuinely more complex than the serotonin hypothesis implies.

SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)

SNRIs block reuptake of both serotonin and norepinephrine, adding noradrenergic effects to serotonergic ones.

Common SNRIs:

• Venlafaxine (Effexor) – at lower doses acts primarily as an SSRI; norepinephrine effects increase at higher doses
• Duloxetine (Cymbalta) – FDA-approved for depression, GAD, fibromyalgia, diabetic peripheral neuropathy, chronic musculoskeletal pain
• Desvenlafaxine (Pristiq) – active metabolite of venlafaxine
• Levomilnacipran (Fetzima) – higher norepinephrine relative to serotonin ratio

When SNRIs are particularly useful:

• Comorbid pain conditions – norepinephrine pathways are involved in descending pain inhibition, making SNRIs particularly effective for depression with chronic pain, fibromyalgia, or neuropathic pain
• When fatigue and concentration are prominent symptoms – norepinephrine has alerting effects
• When adequate SSRI trials haven’t produced full response

Bupropion (Wellbutrin)

Bupropion is mechanistically distinct from SSRIs and SNRIs – it inhibits reuptake of norepinephrine and dopamine (NDRI), without significant serotonin effects.

Key features:

• No sexual side effects (actually may improve libido) – important for patients who can’t tolerate SSRI/SNRI sexual dysfunction
• Activating (may cause initial anxiety or insomnia) – not ideal for highly anxious patients
• May help with fatigue and concentration (dopaminergic effects)
• FDA-approved for smoking cessation (as Zyban) – the same medication at the same dose
• Lowers the seizure threshold at high doses – contraindicated in patients with eating disorders (electrolyte abnormalities increase seizure risk) and seizure history
• Weight neutral or associated with modest weight loss – unlike many antidepressants that cause weight gain

Mirtazapine (Remeron)

Mirtazapine works through an entirely different mechanism – blocking alpha-2 adrenergic autoreceptors (increasing norepinephrine and serotonin release) and blocking specific serotonin and histamine receptors.

Key features:

• Sedating – useful when insomnia is a prominent symptom; usually taken at bedtime
• Increases appetite and causes weight gain – useful in depressed patients with severe anorexia and weight loss; a disadvantage for those already struggling with weight
• Fewer sexual side effects than SSRIs
• Often used as augmentation alongside an SSRI or SNRI, or in older adults where appetite stimulation is beneficial

TCAs (Tricyclic Antidepressants)

Older antidepressants (amitriptyline, nortriptyline, imipramine, clomipramine) that block reuptake of both serotonin and norepinephrine with additional receptor actions (histamine, muscarinic, alpha-1 adrenergic). Effective but with a broader side effect profile:

• Anticholinergic effects: dry mouth, constipation, urinary retention, blurred vision, cognitive effects in older adults
• Sedation (histamine blockade)
• Orthostatic hypotension (alpha-1 blockade) – fall risk in older adults
• Dangerous in overdose – cardiac arrhythmias at toxic doses; not first-line in patients at suicide risk

TCAs retain use for specific indications: neuropathic pain (low-dose amitriptyline), migraine prevention, OCD (clomipramine), and in people who haven’t responded to newer agents.

MAOIs (Monoamine Oxidase Inhibitors)

The oldest class of antidepressants (phenelzine, tranylcypromine, selegiline) – rarely used now due to dietary restrictions and drug interactions, but still valuable in treatment-resistant cases, particularly atypical depression (historically, MAOIs outperformed TCAs in atypical features).

The tyramine restriction: MAOIs inhibit the enzyme that breaks down tyramine in the gut. High-tyramine foods (aged cheeses, cured meats, certain wines, fermented foods) can cause severe hypertensive crisis when consumed with MAOIs. This dietary restriction makes them impractical for many patients.

What to Expect When Starting an Antidepressant

The First 1-2 Weeks: Side Effects Before Benefits

This is the hardest period – and the most common time for people to give up. Side effects often appear before therapeutic effects, creating an initial period where things may feel worse before better.

Common early side effects with SSRIs and SNRIs:

• Nausea (very common, typically improves within 1-2 weeks – taking with food helps)
• Headache
• Initial anxiety or agitation (particularly fluoxetine and venlafaxine)
• Sleep disturbance (insomnia or vivid dreams)
• Dry mouth
• Initial appetite changes

These are usually temporary and resolve within 1-4 weeks. This is the phase where most premature discontinuations occur – and where the importance of knowing what to expect matters most.

Weeks 2-4: Early Improvement

Sleep and energy often improve before mood. Anxiety, irritability, and agitation may begin to settle. Many people notice subtle shifts in their relationship to their negative thoughts – they feel slightly less overwhelming – before mood clearly lifts.

Weeks 4-8: Full Therapeutic Effect

Mood, motivation, and cognitive function typically continue improving through this period. Full response (50% or more symptom reduction) and remission (near-full return to normal functioning) are assessed around weeks 6-8 of adequate dosing.

The adequate dose point matters: Many people don’t achieve the target therapeutic dose if the starting dose is maintained without titration. If response is incomplete at week 4-6, the dose should be optimized before concluding the medication isn’t working.

The Sexual Side Effect Problem

SSRI and SNRI sexual side effects are real, common, and frequently underreported because patients don’t bring them up and prescribers don’t ask.

Estimated prevalence: 30-60% of SSRI users experience at least one sexual side effect, including:

• Reduced libido
• Delayed orgasm or inability to orgasm (anorgasmia)
• Erectile dysfunction in men
• Reduced genital sensitivity
• Reduced vaginal lubrication in women

These side effects often don’t improve with time (unlike nausea or headaches) and can significantly affect quality of life and medication adherence.

Management options:

• Switching to bupropion (no serotonergic sexual effects) or mirtazapine
• Adding bupropion as augmentation to an SSRI
• Dose reduction (if tolerated without symptom recurrence)
• Drug holidays (skipping weekend doses) – only works for short-half-life SSRIs; not safe with paroxetine or venlafaxine
• PDE5 inhibitors (sildenafil, tadalafil) for erectile dysfunction in men on antidepressants

The key message: sexual side effects from antidepressants are manageable and shouldn’t lead to stopping effective treatment without first exploring alternatives.

Weight Changes

Weight gain with antidepressants is common but varies significantly by medication:

The mechanism of SSRI-related weight gain is not fully understood but likely involves effects on appetite regulation, reduced physical activity (if depression improves but motivation for exercise lags), and metabolic effects. It’s most pronounced with longer duration of treatment.

Discontinuation Syndrome: Not the Same as Addiction

“Antidepressant discontinuation syndrome” occurs when antidepressants – particularly those with short half-lives (paroxetine, venlafaxine) – are stopped abruptly. Symptoms include:

• “Brain zaps” (brief electrical shock sensations)
• Dizziness, vertigo
• Flu-like symptoms (nausea, fatigue, muscle aches)
• Irritability and mood changes
• Vivid dreams or nightmares

These symptoms are uncomfortable but not dangerous, and they resolve within 1-4 weeks. They can be largely prevented by tapering the medication slowly rather than stopping abruptly.

This is not the same as addiction or dependency. Antidepressants don’t produce craving, tolerance requiring dose escalation for the same effect, or compulsive drug-seeking behavior. Discontinuation syndrome is a physiological adaptation response – the brain adjusting to the absence of a substance it adapted to, without addiction mechanisms.

Fluoxetine (Prozac) has a uniquely long half-life that provides its own “taper” – discontinuation syndrome is rarely an issue when stopping fluoxetine.

How Long to Take an Antidepressant

First episode MDD: Guidelines recommend continuing antidepressants for at least 6-12 months after achieving remission before considering tapering. Stopping too soon dramatically increases relapse risk.

Recurrent MDD (2+ episodes): Many guidelines recommend longer-term or indefinite maintenance, given the high recurrence risk and evidence that maintenance treatment significantly reduces future episodes.

Anxiety disorders: Often require similar or longer duration than depression. GAD, panic disorder, and social anxiety disorder typically require at least 12 months of treatment after response.

This isn’t about the medication “working” differently over time – it’s that the conditions being treated tend to recur, and treatment reduces that risk.

Frequently Asked Questions

Will antidepressants make me feel like a zombie or numb my emotions? Emotional blunting – feeling emotionally flat or detached – is a real side effect reported by some SSRI users (estimated 30-50% in some surveys, though defining and measuring it is difficult). It’s not the intended effect and it’s not universal. For some people it improves with dose reduction or switching to a different medication. Most people who respond well to antidepressants report feeling more like themselves – the distorting effects of depression are removed – rather than feeling artificially altered.

How do I know if my antidepressant is working? Look for changes in: sleep quality, energy, ability to take interest in activities, ability to concentrate, and gradually in mood. These often shift in that order – sleep and energy first, mood later. Keep notes on your functioning week-by-week. The PHQ-9 (freely available online) provides a structured way to track symptom changes. If there’s no meaningful improvement after 6-8 weeks at an adequate dose, the medication or dose should be reconsidered.

Can I drink alcohol on antidepressants? Alcohol is a CNS depressant that interacts with most antidepressants – increasing sedation, impairing judgment, and potentially worsening depression (alcohol is itself a depressant neurochemically). The interaction doesn’t usually cause dangerous acute toxicity with typical drinks in most people, but alcohol reliably worsens depression outcomes over time and can mask progress. Most prescribers recommend avoiding or significantly limiting alcohol while on antidepressants.

What if the first antidepressant doesn’t work? Approximately 40-50% of people don’t achieve adequate response with the first antidepressant tried. This is expected and not a reason for despair. Options include: dose optimization, switching to a different antidepressant (within or across classes), augmentation (adding a second medication), or adding psychotherapy. The STAR*D trial mapped the reality: about 1/3 of patients achieve remission with the first medication, another 1/3 with the second, and so on through successive trials. Most people eventually find an effective approach.

Are antidepressants safe in pregnancy? This is a nuanced risk-benefit decision that should be made with a psychiatrist or maternal-fetal medicine specialist. Untreated maternal depression also has fetal and infant consequences (stress hormones, behavioral consequences). SSRIs are generally considered the safest pharmacological option in pregnancy when treatment is necessary, though some specific agents (paroxetine) have more concerns. The decision depends on depression severity, prior treatment history, and trimester.

Disclaimer

This article is for educational purposes only and does not constitute medical advice. Antidepressant prescribing, dosing, and management should be directed by a qualified prescriber who knows your complete medical history, current medications, and mental health needs. If you are in crisis, call or text 988 (Suicide and Crisis Lifeline) immediately. Do not start, stop, or adjust antidepressants without medical guidance.

References

1. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder. The Lancet. 2018;391(10128):1357-1366. https://doi.org/10.1016/S0140-6736(17)32802-7
2. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. 2010. https://www.psychiatry.org
3. Clayton AH, Croft HA, Handiwala L. Antidepressants and sexual dysfunction. Postgraduate Medicine. 2014;126(2):91-99. https://doi.org/10.3810/pgm.2014.03.2744
4. Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation. Psychotherapy and Psychosomatics. 2015;84(2):72-81. https://doi.org/10.1159/000370338
5. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps (STAR*D). American Journal of Psychiatry. 2006;163(11):1905-1917. https://doi.org/10.1176/ajp.2006.163.11.1905
6. National Institute of Mental Health (NIMH). Mental health medications. https://www.nimh.nih.gov/health/topics/mental-health-medications
7. Carvalho AF, Sharma MS, Brunoni AR, et al. The safety, tolerability and risks associated with the use of newer generation antidepressant drugs. Psychotherapy and Psychosomatics. 2016;85(5):270-288. https://doi.org/10.1159/000447034
8. MedlinePlus. Antidepressants. https://medlineplus.gov/antidepressants.html
9. Cascade E, Kalali AH, Kennedy SH. Real-world data on SSRI antidepressant side effects. Psychiatry. 2009;6(2):16-18.
10. 988 Suicide and Crisis Lifeline. https://988lifeline.org